Study: NCT03492580

Intervention type: DRUG
Intervention: Empagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Empagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Description: No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Description: No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Description: No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Description: No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.

Intervention type: DRUG
Intervention: Glucagon-like Peptide-1 (GLP-1) Agonist
Description: No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

Intervention type: DRUG
Intervention: Glucagon-like Peptide-1 (GLP-1) Agonist
Description: No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

Intervention type: DRUG
Intervention: Glucagon-like Peptide-1 (GLP-1) Agonist
Description: No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

Intervention type: DRUG
Intervention: Glucagon-like Peptide-1 (GLP-1) Agonist
Description: No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.

Intervention type: DRUG
Intervention: Anti-hyperglycemic Agents (AHA)
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.

Intervention type: DRUG
Intervention: Anti-hyperglycemic Agents (AHA)
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.